Trial overview

SOD1

This trial evaluates the efficacy and safety and of an investigational drug for pre-symptomatic carriers of the SOD1 gene.

Open for participation

PRO-101 trial

Phase 1

In this research we investigate the safety of the new drug prosetin for the treatment of ALS.

Open for participation

MAGNET lithium trial

IIT

UNC13A

The MAGNET lithium trial studies the efficacy of lithium carbonate in ALS patients positive for the homozygous UNC13A mutation.

Open for participation

EPISOD1

Phase 1

SOD1

The EPISOD1 ph 1/2 study evaluates the gene therapy AMMT-162 in participants with SOD1-ALS.

Open for participation

reALiSe

Phase 2

In the reALiSe study the safety and efficacy of the drug ARGX-119 for the treatment of ALS is investigated.

Closed for participation

DAZALS

Phase 2

In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS.

Do you have questions about clinical trials?

Closed for participation

VRG50635 trial

Phase 1

Verge Genomics is conducting a phase 1b trial to evaluate the safety, tolerability, and potential efficacy of VRG50635.

Closed for participation

AP101-02 trial

Phase 2

In this study we investigate the safety, tolerability, pharmacodynamics markers and pharmacokinetics of AP-101 in patients with ALS.

Closed for participation

FUSION

FUS

This study investigates the safety & efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene.

Closed for participation

Lighthouse 2

IIT

The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.

Archived

TUDCA-ALS

IIT

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.